Table 4.
Experimental designs of Parkinson’s disease studies – in vivo
| Ref | Animal | Sex | Weight (g) | N/G | Animal model | Stem cells | Sacrifice | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||||
| Agent | Lesion site | Behavioral analysis
|
Concentration | Im | Time (Week) | Grafting site | Behavioral analysis
|
Type | Week | |||||||
| Drug | Week | Drug | Week | |||||||||||||
| 25 | Rat/SD | M | 250 | 36/6 | 6-OHDA | MFB/VTA | PA | 1 | 2, 5×105 (10 μL) | N/A | N/A | ISt | AP | 2, 4, 6, 8 | 4% PFA | 8 |
| 24 | Rat/SD | M | 220–280 | 40/5 | 6-OHDA | MFB | PA | 2 | 0,5–2, 5×105 (4 μL) | N/A | 2 | ISt | AP | 0, 1, 4, 8 | 4% PFA | 12 |
| 22 | Rat/SD | M | 260–300 | 63 | 6-OHDA+De | ISt | N/A | 1 | 1, 5–4, 5×105 (3 μL) | CC (15) | 1 | ISt | AF | 2, 4, 6 | 4% PFA | 1, 5, 7.1 |
| 21 | Rat/SD | M | 250–300 | 12/2 | 6-OHDA+De | ISt | MA | 1 | 5×104 (5 μL) | CC (2.5) | 2 | ISt | MA | 2 | 4% PFA | 6 |
| 23 | Rat/Wistar | M | 190–210 | 13/2 | 6-OHDA | MFB | AF | 4 | 1×105 (3 μL) | N/A | 3 | ISt | AF | 5, 7, 9 | 4% PFA | 2, 3.4, 10 |
| 20 | Rat/SD | M | 250–300 | 18/3 | 6-OHDA | MFB | PA | 2, 4, 6 | 1×107 (3 μL) | CC (15) | 6 | ISt | AF | 1, 2, 4, 6, 8, 10 | 4% PFA | 10 |
| 19 | Rat/SD | M | 200–250 | 28/2 | 6-OHDA+De | MFB | AF | 5, 7 | 1–2×103 (4 μL) | CC (15) | 3 | ISt | AF | 4 | 4% PFA | 12 |
Abbreviations: Ref, reference; SD, Sprague-Dawley; M, male; N/G, number of animals/groups; 6-OHDA, 6-hydroxydopamine; +De, Desipramine 25 mg/kg intraperitoneal; MFB, medial forebrain bundle; ISt, intrastriatal; AF, amphetamine; AP, apomorphine; MA, methamphetamine; Im, immunosuppression (mg/kg); CC, cyclosporine A; PFA, paraformaldehyde; VTA, ventral tegmental area; N/A, not identified.